A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya
Formáid: Artigo
Teanga:Béarla
Foilsithe / Cruthaithe: 2025
Rochtain ar líne:https://doi.org/10.1183/13993003.02231-2024
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Ar líne

https://doi.org/10.1183/13993003.02231-2024

Míreanna comhchosúla